Epstein-Barr virus latent membrane protein 1 peptide-HLA complex (LMP1-HLA) (LMP1-HLA complex)

The Epstein-Barr virus latent membrane protein 1 (LMP1) peptide-HLA complex is a specialized immunological target consisting of a processed fragment of the LMP1 viral protein bound to a Human Leukocyte Antigen (HLA) molecule on the cell surface. LMP1 is a primary oncogene of the Epstein-Barr virus (EBV) that functions as a constitutively active mimic of the CD40 receptor, driving cell growth and survival through the activation of NF-κB, PI3K/Akt, and MAPK pathways (PMID: 25407632). Because the full-length LMP1 protein has limited extracellular accessibility, the presentation of its processed peptides (such as the HLA-A*02:01-restricted YLLEMLWRL) on the cell surface provides a unique window for therapeutic intervention (PMID: 15163936). This complex is highly specific to EBV-infected cells and is expressed in various malignancies, including nasopharyngeal carcinoma and certain lymphomas. Current drug development efforts focus on engineering T-cell receptor (TCR)-based therapies and TCR-like antibodies that can recognize this specific peptide-MHC configuration to induce targeted cell lysis (PMID: 33060330). These therapies represent a promising approach to treating EBV-associated cancers while minimizing damage to healthy, non-infected tissues.

Other names

EBV LMP1-MHC complexLMP1-HLA-A*02:01Latent membrane protein 1 peptide-HLA complexEBV LMP1 pMHC

Targeting of the peptide-MHC complex by engineered T-cells (TCR-T or CAR-T) or TCR-like antibodies to induce direct cytotoxic lysis of EBV-infected or transformed cells.